Lilly, which reported its China revenues climbed 31% in 2011, hopes to raise the China contribution to its total revenues from a current 2% up to 4%. In dollars, that will bring the company from about $500 million to $1 billion in China revenues. “Our goal is to be the fastest growing pharmaceutical company in China,” CEO John Lechleiter said in a recent Beijing briefing. “We are increasing our investments in every aspect of our business.” Taking an unusual path for a big pharma, Lilly also said it hopes to form partnerships with China drug distributors. More details....

Stock Symbol: (NYSE: LLY)

Share this with colleagues: